SCHEMBL4414854

SCHEMBL4414854

C[CH]c1ccc(Oc2ccc(Cl)cc2Cl)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 3/20 0.49
TTR P02766 5/20 0.49
MAPT P10636 3/20 0.47
HPGD P15428 2/20 0.47
NR1I2 O75469 1/20 0.47
LMNA P02545 1/20 0.47
PGR P06401 1/20 0.47
HSP90AA1 P07900 1/20 0.47
ADORA3 P0DMS8 1/20 0.47
HSPA5 P11021 1/20 0.47
CBR1 P16152 1/20 0.47
TBXA2R P21731 1/20 0.47
SLC6A2 P23975 1/20 0.47
AGTR1 P30556 1/20 0.47
SLC6A3 Q01959 1/20 0.47
CYP1A2 P05177 2/20 0.46
CYP2C9 P11712 2/20 0.46
CYP2C19 P33261 2/20 0.46
KDM4E B2RXH2 1/20 0.46
MEN1 O00255 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3438989 0.83 MAPT (0.62) FFAR1TTRMAPTHPGDNR1I2
SCHEMBL9265274 0.83 TTR (0.65) FFAR1TTRMAPTHPGDNR1I2
SCHEMBL16705542 0.80 HTR2A (0.55) FFAR1TTRMAPTHPGDNR1I2
SCHEMBL23244718 0.80 FFAR1 (0.54) FFAR1TTRMAPTLMNAKDM4E
SCHEMBL7040563 0.79 MAOB (0.52) MAPTHPGDLMNACYP1A2CYP2C9
SCHEMBL21620367 0.77 FFAR1 (0.65) FFAR1TTRMAPTHPGDNR1I2
SCHEMBL3469104 0.77 TTR (0.61) FFAR1TTRMAPTHPGDNR1I2
SCHEMBL2092929 0.77 FFAR1 (0.53) FFAR1TTRMAPTHPGDNR1I2
SCHEMBL554810 0.77 MAOA (0.61) FFAR1TTRMAPTHPGDNR1I2
SCHEMBL8502158 0.77 FFAR1 (0.56) FFAR1TTRMAPTHPGDNR1I2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1299354-B1 FACTOR VIIA INHIBITORY (THIO)UREA DERIVATIVES, THEIR PREPARATION AND THEIR USE SANOFI AVENTIS DEUTSCHLAND (DE) 2009-07-22 EP claimed
US-11629129-B2 Microbiocidal picolinamide derivatives SYNGENTA PARTICIPATIONS AG (CH) 2023-04-18 US disclosed
US-20210114984-A1 MICROBIOCIDAL PICOLINAMIDE DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2021-04-22 US disclosed
EP-1299354-B1 FACTOR VIIA INHIBITORY (THIO)UREA DERIVATIVES, THEIR PREPARATION AND THEIR USE SANOFI AVENTIS DEUTSCHLAND (DE) 2009-07-22 EP disclosed
US-6743790-B2 A UREA OR THIOUREA DERIVATIVES CONTAINING AMIDE GROUP USEFUL AS ANTICOAGULANTS AND ANTIINFLAMMATORY AGENTS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-06-01 US disclosed
EP-1299354-A2 FACTOR VIIA INHIBITORY (THIO)UREA DERIVATIVES, THEIR PREPARATION AND THEIR USE Aventis Pharma Deutschland GmbH (DE) 2003-04-09 EP disclosed
WO-2001094301-A2 FACTOR VIIA INHIBITORY (THIO)UREA DERIVATIVES, THEIR PREPARATION AND THEIR USE AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2001-12-13 WO disclosed
EP-1162194-A1 Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use Aventis Pharma Deutschland GmbH (DE) 2001-12-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210114984-A1 MICROBIOCIDAL PICOLINAMIDE DERIVATIVES PRF1, CASP1, MSR1 FFAR1 211/4885TTR 2468/4885MAPT 3592/4885
US-11629129-B2 Microbiocidal picolinamide derivatives PRF1, CASP1, MSR1 FFAR1 211/4885TTR 2468/4885MAPT 3592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.